BioSpace News Archive

Neurona Therapeutics will use the funds to advance its investigational regenerative neural cell therapy NRTX-1001 for mesial temporal lobe epilepsy, the most common form of focal epilepsy.

The CEOs of BMS, J&J and Merck testified Thursday before the Senate health committee that pharmacy benefit managers bear much of the blame for high pricing, while declining to commit to price cuts.

Despite not having a single candidate in the clinical stage, the Moderna-backed biotech is offering 6.25 million shares for $15 apiece in an initial public offering. Shares are expected to begin trading Friday.

Investors drove up the price of Kyverna Therapeutics’ stock by 59% in its initial public offering on Thursday afternoon, the first day of trading, reaching a peak per-share price of $35.01.

Madrigal Pharmaceuticals announced late-stage results published Thursday in The New England Journal of Medicine for resmetirom as it awaits a March 14 PDUFA date.

Biopharma’s latest earnings season was, in a word, predictable. Companies are consistently beating Wall Street earnings and revenue estimates as they set low expectations for investors.

Following promising Phase IIb studies, Takeda will advance its oral ORX2 agonist TAK-861 into Phase III studies for narcolepsy type 1, while nixing the candidate’s development in narcolepsy type 2.

Sensorion announced a €50.5 million offering reserved to specific categories of investors through the issuance of 88,594,737 new ordinary shares of the Company at a price per New Share of €0.57 to the benefit of Redmile Group, Invus and Sofinnova Partners, existing shareholders, and leading US Healthcare Specialists funds including Aquilo Capital, as well as two large investment management firms.

USC, together with Leonard and his late wife Pamela Schaeffer, is launching a new institute to be anchored in Los Angeles and in the university’s new Capital Campus in Washington, D.C.

Hemogenyx Pharmaceuticals plc is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration that it has lifted the clinical hold on the Investigational New Drug application for HEMO-CAR-T for the treatment of acute myeloid leukemia.